March 2020 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2019/20 Invitation to Tender, dated 1 November 2019.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by:
- For new listings, by 4pm on 12 April 2020 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
PHARMAC cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2019/20 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2023
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand |
Date of subsidy change |
Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
|
Potassium iodate |
Tab 253 mcg (150 mcg elemental iodine); 90 tablet bottle pack |
$4.69 |
$4.58 |
NeuroTabs |
1 July 2020 |
1 October 2020 |
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand (Supplier) |
Date of listing |
Sole Subsidised Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Benzatropine mesylate |
Inj 1 mg per ml, 2 ml; |
$95.00 (per 5 pack – Cogentin) |
$95.00 |
Phebra |
1 July 2020 |
1 December 2020 |
Cogentin (A. Menarini) |
|
Leflunomide |
Tab 10 mg; |
$2.90 |
$6.00 |
Arava |
1 July 2020 |
1 December 2020 |
Apo-Leflunomide (Apotex) |
|
Leflunomide |
Tab 20 mg; |
$2.90 |
$6.00 |
Arava |
1 July 2020 |
1 December 2020 |
Apo-Leflunomide (Apotex) |
|
Pravastatin |
Tab 20 mg; |
$4.72 (per 100 tablet pack) |
$2.26 |
Pravastatin Mylan |
1 November 2020 |
1 April 2021 |
Apo-Pravastatin (Apotex) |
|
Pravastatin |
Tab 40 mg; |
$8.06 (per 100 tablet pack) |
$3.87 |
Pravastatin Mylan |
1 November 2020 |
1 April 2021 |
Apo-Pravastatin (Apotex) |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Bupivacaine hydrochloride |
Inj 2.5 mg per ml, 20 ml ampoule, sterile pack; |
$29.20 |
$23.36 |
Marcain (Aspen Pharma) |
1% |
1 May 2020 |
1 August 2020 |
|
Bupivacaine hydrochloride |
Inj 5 mg per ml, 10 ml ampoule, sterile pack; |
$20.25 |
$16.20 |
Marcain (Aspen Pharma) |
1% |
1 May 2020 |
1 August 2020 |
|
Bupivacaine hydrochloride |
Inj 5 mg per ml, 20 ml ampoule, sterile pack; |
$20.70 |
$16.56 |
Marcain (Aspen Pharma) |
1% |
1 May 2020 |
1 August 2020 |
|
Bupivacaine hydrochloride |
Inj 2.5 mg per ml, 100 ml bag; |
$150.00 |
$150.00 |
Marcain (Aspen Pharma) |
1% |
1 July 2020 |
1 October 2020 |
|
Bupivacaine hydrochloride |
Inj 5 mg per ml, 4 ml ampoule; |
$50.00 |
$50.00 |
Marcain Isobaric (Aspen Pharma) |
1% |
1 July 2020 |
1 October 2020 |
|
Potassium iodate |
Tab 253 mcg (150 mcg elemental iodine); 90 tablet bottle pack |
$4.69 |
$4.58 |
NeuroTabs (AFT) |
1% |
1 July 2020 |
1 October 2020 |
4. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Hospital supply brand (Supplier) |
DV Limit |
Listing date |
Hospital Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Benzatropine mesylate |
Inj 1 mg per ml, 2 ml vial; |
$95.00 |
$95.00 |
Phebra |
1% |
1 July 2020 |
1 December 2020 |
Cogentin (A. Menarini) |
|
Dexmedetomidine |
Inj 100 mcg per ml, 2 ml vial; |
$357.00 |
$97.88 |
Dexmedetomidine-Teva |
1% |
1 October 2020 |
1 March 2021 |
Precedex (Pfizer) |
|
Leflunomide |
Tab 10 mg; |
$2.90 |
$6.00 |
Arava |
1% |
1 July 2020 |
1 December 2020 |
Apo-Leflunomide (Apotex) |
|
Leflunomide |
Tab 20 mg; |
$2.90 |
$6.00 |
Arava |
1% |
1 July 2020 |
1 December 2020 |
Apo-Leflunomide (Apotex) |
|
Pravastatin |
Tab 20 mg; |
$4.72 (per 100 tablet pack) |
$2.26 |
Pravastatin Mylan |
1% |
1 November 2020 |
1 April 2021 |
Apo-Pravastatin (Apotex) |
|
Pravastatin |
Tab 40 mg; |
$8.06 (per 100 tablet pack) |
$3.87 |
Pravastatin Mylan |
1% |
1 November 2020 |
1 April 2021 |
Apo-Pravastatin (Apotex) |
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:
- the 2019/20 Invitation to Tender, dated 1 November 2019
2019/20 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Alfacalcidol |
Cap 0.25 mcg |
|
Alfacalcidol |
Cap 1 mcg |
|
Alfacalcidol |
Oral drops 2 mcg per ml |
|
Alprostadil |
Inj 10 mcg |
|
Alprostadil |
Inj 20 mcg |
|
Betamethasone Dipropionate |
Crm 0.05% in propylene glycol base |
|
Betamethasone Dipropionate |
Oint 0.05% in propylene glycol base |
|
Betamethasone Dipropionate |
Crm 0.05% (pack size 30 g or less) |
|
Betamethasone Dipropionate |
Oint 0.05% (pack size 30 g or less) |
|
Betamethasone Sodium Phosphate with Betamethasone Acetate |
Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1ml |
|
Bismuth trioxide |
Tab |
|
Budesonide (current access) |
Cap 3 mg modified release |
|
Budesonide (widened access) |
Cap 3 mg modified release |
|
Calcium folinate |
Tab 15 mg |
|
Calcium Gluconate |
Inj 10%, 10 ml |
|
Calcium Gluconate |
Gel 2.5% |
|
Cidofovir |
Inj 75 mg per ml, 5 ml |
|
Ciprofloxacin |
Ear drops 0.3% |
|
Citric acid with magnesium oxide and sodium picosulfate |
Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet |
|
Cycloserine |
Cap 250 mg |
|
Desmopressin |
Tab 100 mcg |
|
Diflucortolone Valerate |
Crm 0.1% |
|
Diflucortolone Valerate |
Fatty oint 0.1% |
|
Dosulepin [Dothiepin] Hydrochloride |
Tab 75 mg |
|
Dosulepin [Dothiepin] Hydrochloride |
Cap 25 mg |
|
Doxazosin mesylate |
Tab 2 mg |
|
Doxazosin mesylate |
Tab 4 mg |
|
Ergometrine maleate |
Inj 500 mcg per ml, 1 ml |
|
Ergometrine maleate |
Inj 250 mcg per ml, 1 ml ampoule |
|
Etravirine |
Tab 200 mg |
|
Fexofenadine |
Tab 120 mg |
|
Fexofenadine |
Tab 60 mg |
|
Fluconazole |
Powder for oral suspension 10 mg per ml |
|
Flupenthixol Decanoate |
Inj 20 mg per ml, 1 ml |
|
Flupenthixol Decanoate |
Inj 20 mg per ml, 2 ml |
|
Flupenthixol Decanoate |
Inj 100 mg per ml, 1 ml |
|
Fosfomycin |
Powder for oral solution, 3 g sachet |
|
Framycetin sulphate |
Ear/Eye drops 0.5% |
|
Gemfibrozil |
Tab 600 mg |
|
Glyceryl trinitrate |
Inj 1 mg per ml, 5 ml - 10 ml |
|
Ketoconazole |
Tab 200 mg |
|
Lopinavir with Ritonavir |
Tab 200 mg with ritonavir 50 mg |
|
Lopinavir with ritonavir |
Tab 100 mg with ritonavir 25 mg |
|
Miconazole nitrate |
Lotn/tincture 2% |
|
Nicotinic acid |
Tab 50 mg |
|
Nicotinic acid |
Tab 500 mg |
|
Norfloxacin |
Tab 400 mg |
|
Oxazepam |
Tab 10 mg |
|
Oxazepam |
Tab 15 mg |
|
Paliperidone (one-monthly depot injection) |
Inj 25 mg syringe |
|
Paliperidone (one-monthly depot injection) |
Inj 50 mg syringe |
|
Paliperidone (one-monthly depot injection) |
Inj 75 mg syringe |
|
Paliperidone (one-monthly depot injection) |
Inj 100 mg syringe |
|
Paliperidone (one-monthly depot injection) |
Inj 150 mg syringe |
|
Paliperidone (three-monthly depot injection) |
Inj 175 mg syringe |
|
Paliperidone (three-monthly depot injection) |
Inj 250 - 300 mg syringe |
|
Paliperidone (three-monthly depot injection) |
Inj 350 mg syringe |
|
Paliperidone (three-monthly depot injection) |
Inj 500 mg or greater syringe |
|
Pantoprazole |
Inj 40 mg |
|
Paper wasp venom |
Inj with diluent for extract |
|
Paper wasp venom |
Treatment kit |
|
Pericyazine |
Tab 2.5 mg |
|
Pericyazine |
Tab 10 mg |
|
Phenothrin |
Shampoo 0.5% |
|
Phenoxybenzamine |
Cap 10 mg |
|
Polyvinyl alcohol |
Eye drops 1.4% |
|
Polyvinyl alcohol |
Eye drops 3% |
|
Prednisone |
Tab 1 mg |
|
Prednisone |
Tab 2.5 mg |
|
Prednisone |
Tab 20 mg |
|
Prednisone |
Tab 5 mg |
|
Prilocaine Hydrochloride |
Inj 2%, 5 ml ampoule |
|
Pyridoxine hydrochloride |
Tab 50 mg |
|
Pyrimethamine |
Tab 25 mg |
|
Selexipag |
Tab 200 mcg |
|
Selexipag |
Tab 400 mcg |
|
Selexipag |
Tab 800 mcg |
|
Selexipag |
Tab 1000 mcg |
|
Selexipag |
Tab 1200 mcg |
|
Selexipag |
Tab 1400 mcg |
|
Selexipag |
Tab 1600 mcg |
|
Selexipag |
Tab 600 mcg |
|
Sodium Acid Phosphate |
Enema 16% with sodium phosphate 8% |
|
Streptomycin sulphate |
Inj 400 mg per ml, 2.5 ml |
|
Sulfadiazine Sodium |
Tab 500 mg |
|
Terazosin hydrochloride |
Tab 1 mg |
|
Terazosin hydrochloride |
Tab 2 mg |
|
Terazosin hydrochloride |
Tab 5 mg |
|
Testosterone cypionate |
Inj long-acting 100 mg per ml, 10 ml |
|
Thyrotropin alfa |
Inj 900 mcg vial |
|
Timolol |
Tab 10 mg |
|
Tobramycin |
Powder BP |
|
Tobramycin |
Inj 100 mg per ml, 5 ml |
|
Triamcinolone acetonide with gramicidin, neomycin and nystatin |
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g |
|
Triazolam |
Tab 125 mcg |
|
Triazolam |
Tab 250 mcg |
|
Vancomycin hydrochloride |
Inj 1 g |
|
Wool fat with mineral oil |
Lotn hydrous 3% with mineral oil, 1000 ml |
|
Zinc and castor oil |
Crm (pack size 50 g or less) |
|
Zinc and castor oil |
Crm (pack size greater than 50 g) |
|
Zolmitriptan |
Nasal Spray |
For products included in the 2017/18 and 2018/19 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.